HCW Biologics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-8.0M | $-30.0M | $-25.0M | $-14.9M | $-12.9M | $-5.8M |
| Depreciation & Amortization | $1.0M | $1.2M | $1.1M | $717.9K | $543.6K | $572.9K |
| Depreciation | $507.0K | $644.6K | $794.6K | $589.6K | $543.6K | $572.9K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $768.6K | $1.0M | $1.0M | $1.1M | $361.0K | $21.9K |
| Net Cash from Operating Activities | $-13.4M | $-14.2M | $-22.5M | $-10.4M | $-11.0M | $-10.4M |
| Investing Activities | ||||||
| Capital Expenditures | $0 | $261.6K | $6.2M | $10.3M | $47.3K | $186.7K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $-261.6K | $3.8M | $14.7M | $-35.0M | $-186.7K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $10.7M | $15.6M | $-14.5K | $6.3M | $49.3M | $11.7M |
| Net Change in Cash | $-2.7M | $1.1M | $-18.7M | $10.6M | $3.3M | $1.1M |
| Free Cash Flow | $-13.4M | $-14.5M | $-28.7M | $-20.7M | $-11.0M | $-10.6M |